RFID still garners big forecast

Vendors are offering pilot kits to help drugmakers get a handle on the little understood business case for RFID technology. Delays in retailer and regulatory supply chain mandates have hampered adoption, says GBI Research, which forecasts annual industry growth of 34 percent through 2015, in a $3,500 report. Release

Suggested Articles

South Korea’s Celltrion, which has a massive biologics site in Songdo, has decided it is time to build some operations in China.

WuXi Biologics is taking control of a Bayer plant in Germany and agreed it could serve as a backup facility for supply of hemophilia drug Kovaltry.

A Chinese OTC drugmaker gets the distinction of ringing in the new year as the first company to be slapped with an FDA warning letter.